high-risk

2:55
Molecular therapy stratification for high-risk MM: MUK Nine b OPTIMUM
Martin Kaiser
1:38
Ibrutinib and venetoclax upfront for high-risk CLL
Nitin Jain
1:38
Daratumumab with IRd in NDMM displays excellent activity
Morie Gertz
0:49
Myeloma: tackling high-risk disease
Amrita Krishnan
0:39
Genomic advances in MM disease biology
Irene Ghobrial
1:53
Nivolumab with ibrutinib for Richter’s transformation
Nitin Jain
2:24
Better together? Ibrutinib and venetoclax for high-risk CLL
Nitin Jain
2:33
Treatment options for high-risk myeloma
Annemiek Broyl
1:56
How do we define a ‘cure’ in myeloma?
Annemiek Broyl
2:48
MRD and disease eradication in myeloma
Jesús San Miguel
1:59
Smoldering multiple myeloma: what is the current definition & new screening programme
Irene Ghobrial
2:32
Improving the treatment landscape for DLBCL patients
Andrés Ferreri
2:14
How to define and treat high-risk lymphoma
Andrés Ferreri
2:08
Eradicating GvHD after haploidentical stem cell transplant
Denis-Claude Roy
1:56
Implications for a technique which eliminates GvHD
Denis-Claude Roy
1:58
Logistics for a technique to avoid GvHD
Denis-Claude Roy
VJHemOnc VJHemOnc is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter

Subscribe now
The content of VJHemOnc is intended for healthcare professionals